企業概要
DarioHealth Corp. operates as a digital health company serving markets in the United States and internationally, utilizing a digital therapeutics platform to deliver personalized interventions driven by data analytics and coaching for conditions such as diabetes, hypertension, and weight management. The enterprise functions within the healthcare sector, specifically categorized under health information services, where it provides technological solutions to address chronic disease management and patient engagement. According to the most recent data, the company holds a market capitalization of $51.83M and generates annual revenue of $22.36M based on trailing twelve-month figures. With an employee base of 160, DarioHealth's financial scale indicates a small-cap status, suggesting a position that relies on specialized niche solutions rather than broad market dominance, which often characterizes early-stage or growth-oriented digital health entities.
財務健全性
The company reported a revenue of $22.36M over the trailing twelve months, yet it incurred a net income of $-40,309,576, highlighting a significant divergence between top-line activity and bottom-line profitability that reveals a highly aggressive or inefficient cost structure. EBITDA stood at $-33,517,000, indicating that even before interest, taxes, depreciation, and amortization, the core operations generated negative cash earnings. Free cash flow was recorded at $-11,204,875, which signifies that the company is currently burning cash rather than generating surplus liquidity for reinvestment or debt servicing. Gross margin stands at 64.1%, suggesting that the cost of goods sold is relatively contained compared to revenue, whereas the operating margin of -163.7% and profit margin of -186.6% demonstrate severe operational losses where operating expenses substantially exceed revenue generation. On the balance sheet, the company holds $26.02M in cash against $31.75M in debt, resulting in a debt-to-equity ratio of 46.74, which characterizes a highly leveraged financial position where liabilities significantly outweigh equity capital. Despite the leverage, the current ratio is 3.76, indicating strong short-term liquidity as current assets are more than three times the value of current liabilities. Return on Equity is -59.6% and return on assets is -20.0%, metrics that reveal management has not yet achieved profitability on the invested capital or asset base, reflecting the challenges typical of loss-making biotech or digital health firms.
バリュエーション評価
Trailing twelve-month P/E ratio is N/A due to negative net income, while the forward P/E is listed as -16.32, a metric that implies earnings expectations remain negative and traditional price-to-earnings valuation models are currently inapplicable. The price-to-book ratio is 0.72, indicating that the market values the company's equity at a discount to its book value, which may reflect skepticism regarding future earnings potential or asset quality. Alternative valuation metrics such as the price-to-sales ratio of 2.32 and an EV/EBITDA of -1.72 suggest that investors are pricing the stock based on revenue multiples rather than earnings power, given the lack of current profitability. The 52-week high was $17.74 and the low was $5.93, placing the current valuation within a range that has seen significant volatility over the past year. With a beta of 1.28, the stock exhibits price volatility that is higher than the broader market, meaning it tends to amplify market movements with greater intensity than large-cap healthcare peers.
Growth & Income
Revenue growth year-over-year contracted by 31.2%, while earnings growth is N/A, indicating that the company is currently in a contraction phase rather than an expansion period. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, which reflects a strategy of retaining all cash flow to fund operations rather than distributing income to shareholders. The absence of a dividend program confirms that the company reinvests its limited financial resources into its digital therapeutics platform and operational infrastructure in an attempt to achieve future profitability. Overall, the growth and income profile is characterized by revenue contraction, negative earnings, zero dividend yield, and a high-beta volatility structure that presents a high-risk, non-income-generating asset class.